Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.83 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367834 | 0.91 | RPS6KB1 (0.83) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3546112 | 0.87 | MAPK14 (1.00) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3547903 | 0.86 | MAPK14 (1.00) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4363639 | 0.86 | RPS6KB1 (0.75) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4371871 | 0.85 | RPS6KB1 (0.71) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3545324 | 0.82 | MAPK14 (0.82) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3546504 | 0.82 | MAPK14 (0.75) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4375156 | 0.82 | RPS6KB1 (0.70) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4368714 | 0.81 | MAPK14 (0.75) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3549747 | 0.81 | MAPK14 (0.81) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | RPS6KB1 207/4885MAPK14 47/4885MAPK13 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.